部分论文 1、遗传基因变异与癫癎,《中国当代儿科杂志》,2017年19卷9期 952-955页,第一作者 2、维吾尔族、汉族癫痫患儿左乙拉西坦血药浓度与疗效及安全性的相关性研究, 《中国现代应用药学》 2019年36卷5期 594-599页,通讯作者 3、新疆癫痫患儿拉莫三嗪稳态血药浓度影响因素的研究,《中国临床药理学杂志》,2021年37卷15期 1981-1984页,第一作者 4、Congenital muscular dystrophies in China. Clin Genet.2019,96(3):207-215.通讯作者 5、Association between HLA genotype and antiseizure medications (ASMs)- induced maculopapular eruption among epilepsy patients in Xinjiang, China,Epilepsy Research ,165 (2020) 106391.通讯作者 6、The Association Between HLA-A*03:01 and HLA-B*07:02 Alleles and Oxcarbazepine-induced Maculopapular Eruption in the Uighur Chinese Population. Seizure: European Journal of Epilepsy 81 (2020) 43–46.通讯作者 7、Long-term safety, efficacy, and tolerability of levetiracetam in pediatric patients with epilepsy in Uygur, China: A retrospective analysis,Epilepsy Behavior ,120 (2021) 108010.通讯作者 8、Development and validation of an innovative UPLC method to quantify lacosamide, oxcarbazepine, and lamotrigine in the serum of children with epilepsy in China.Biomed Chromatogr.2021 Apr ;35(4):e5022,2021 Apr ;35(4):e5022.通讯作者 9、Development and application of a novel LC–MS/MS method for human plasma concentration monitoring of perampanel in pediatric epilepsy patients.Biomedical Chromatography. 2022;36:e5446.通讯作者 10、Impact of ABCB1 Polymorphisms on Lacosamide Serum Concentrations in Uygur Pediatric Patients With Epilepsy in China. Ther Drug Monit _ Volume 44, Number 3, June 2022.通讯作者 11、Twelve-month efficacy of lacosamide monotherapy at maximal dose and tolerability for epilepsy treatment in pediatric patients: Real-world clinical experience. Pediatric Neurology.Available online 6 February 2023. 通讯作者 科研项目: 1、CAAE癫痫科研基金—UCB基金(201804):新疆癫痫患儿左乙拉西坦稳态血药浓度影响因素探讨及参考区间的初步建立研究.排名第一 2、国自然(项目批准号81460571):人类白细胞抗原基因与卡马西平等药物诱发皮肤型药物不良反应相关性在新疆维、汉民族患者间的差异性研究.排名第二 3、CAAE癫痫科研基金—UCB基金(201407):左乙拉西坦治疗维吾尔族癫痫患儿血药浓度与疗效、安全性评价. 排名第一 4、自治区科技支疆项目(编号:2021e02065)新生儿重症监护病房神经损伤高危儿及新生儿脑损伤精准防控 |